

EP7-A2
Vol. 25 No. 27
Replaces EP7-A
Vol. 22 No. 27

Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition

This document provides background information, guidance, and experimental procedures for investigating, identifying, and characterizing the effects of interfering substances on clinical chemistry test results.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



*(Formerly NCCLS)
Providing NCCLS standards and guidelines,
ISO/TC 212 standards, and ISO/TC 76 standards*

Clinical and Laboratory Standards Institute

Providing NCCLS standards and guidelines, ISO/TC 212 standards, and ISO/TC 76 standards

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most documents are subject to two levels of consensus—“proposed” and “approved.” Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI’s established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.

EP7-A2
ISBN 1-56238-584-4
ISSN 0273-3099

Volume 25 Number 27

Interference Testing in Clinical Chemistry; Approved Guideline— Second Edition

Robert J. McEnroe, PhD
Mary F. Burritt, PhD
Donald M. Powers, PhD
Douglas W. Rheinheimer, MT
Brian H. Wallace, PhD

Abstract

Clinical and Laboratory Standards Institute document EP7-A2—*Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition* is intended to promote uniformity in the evaluation of interference characteristics of clinical laboratory measurement procedures. EP7 describes procedures for manufacturers to screen potentially interfering substances, to quantify interference effects, and to confirm interference in patient samples. This document also describes procedures for clinical laboratories to verify interference claims, and to investigate discrepant results caused by unsuspected interfering substances. Detailed examples are given. EP7 also contains background information on interference testing concepts, tables of recommended test concentrations for analytes and potential interference, and data collection and analysis worksheets.

Clinical and Laboratory Standards Institute (CLSI). *Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition*. CLSI document EP7-A2 (ISBN 1-56238-584-4). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2005.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI/NCCLS documents. Current editions are listed in the CLSI catalog, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



(Formerly NCCLS)
Providing NCCLS standards and guidelines,
ISO/TC 212 standards, and ISO/TC 76 standards

This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute, except as stated below.

Clinical and Laboratory Standards Institute hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from CLSI publication EP7-A2—*Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition* (ISBN 1-56238-584-4). Copies of the current edition may be obtained from Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from Clinical and Laboratory Standards Institute by written request. To request such permission, address inquiries to the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2005. Clinical and Laboratory Standards Institute.

Suggested Citation

(Clinical and Laboratory Standards Institute. *Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition*. CLSI document EP7-A2 [ISBN 1-56238-584-4]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2005.)

Proposed Guideline

August 1986

Approved Guideline

December 2002

Approved Guideline—Second Edition

November 2005

ISBN 1-56238-584-4

ISSN 0273-3099

Committee Membership

Area Committee on Evaluation Protocols

Luann Ochs, MS
Chairholder
Roche Diagnostics Corporation
Indianapolis, Indiana

Jan S. Krouwer, PhD
Vice-Chairholder
Krouwer Consulting
Sherborn, Massachusetts

George S. Cembrowski, MD, PhD
 Provincial Laboratory for Public Health
 Edmonton, Alberta, Canada

David L. Duewer, PhD
 National Institute of Standards and Technology
 Gaithersburg, Maryland

Anders Kallner, MD, PhD
 Karolinska Hospital
 Stockholm, Sweden

Jacob (Jack) B. Levine, MBA
 Bayer Corporation
 Tarrytown, New York

Kristian Linnet, MD, PhD
 Psychiatric University Hospital
 Risskov, Denmark

Kristen L. Meier, PhD
 FDA Center for Devices and Radiological Health
 Rockville, Maryland

Daniel W. Tholen, MS
 Dan Tholen Statistical Consulting
 Traverse City, Michigan

Advisors

David A. Armbruster, PhD,
 DABCC, FACB
 Abbott Laboratories
 Abbott Park, Illinois

R. Neill Carey, PhD, FACB
 Peninsula Regional Medical Center
 Salisbury, Maryland

Carl C. Garber, PhD, FACB
 Quest Diagnostics, Incorporated
 Lyndhurst, New Jersey

Patricia E. Garrett, PhD
 Boston Biomedica, Inc.
 Portland, Maine

Martin H. Kroll, MD
 Dallas VA Medical Center
 Dallas, Texas

Donald M. Powers, PhD
 Powers Consulting Services
 Pittsford, New York

Max Robinowitz, MD
 FDA Center for Devices and Radiological Health
 Rockville, Maryland

Gian Alfredo Scassellati, PhD
 Ente Nazionale Italiano Di Unificazione
 Turin, Italy

Jack Zakowski, PhD
 Beckman Coulter, Inc.
 Brea, California

Working Group on Interference Testing

Robert J. McEnroe, PhD
Chairholder
Roche Diagnostics Operations, Inc.
Indianapolis, Indiana

Mary E. Burritt, PhD
 Mayo Clinic
 Rochester, Minnesota

Donald M. Powers, PhD
 Powers Consulting Services
 Pittsford, New York

Douglas W. Rheinheimer, MT
 FDA Center for Devices and Radiological Health
 Rockville, Maryland

Brian H. Wallace, PhD
 LifeScan, Inc.
 Milpitas, California

Staff

Clinical and Laboratory Standards Institute
 Wayne, Pennsylvania

John J. Zlockie, MBA
Vice President, Standards

Lois M. Schmidt, DA
Staff Liaison

Donna M. Wilhelm
Editor

Melissa A. Lewis
Assistant Editor

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
2.1 Measurement Procedures.....	1
2.2 Concepts and Scientific Principles.....	2
3 Standard Precautions.....	4
4 Definitions.....	5
5 Decision Criteria for Interference Testing.....	8
5.1 Clinical Acceptability Criteria.....	9
5.2 Statistical Significance and Power.....	9
5.3 Analyte Test Concentrations.....	10
5.4 Potential Interfering Substances.....	10
5.5 Interferent Test Concentrations.....	11
6 Quality Assurance and Safety.....	12
6.1 Training and Familiarization.....	12
6.2 Precision Verification.....	12
6.3 Trueness Verification.....	12
6.4 Carryover Assessment.....	12
6.5 Quality Control.....	12
6.6 Safety and Waste Disposal.....	13
7 Estimation of Interference Characteristics.....	13
7.1 Interference Screen.....	13
7.2 Characterization of Interference Effects.....	20
7.3 Evaluating Combinations of Analyte and Interferent(s).....	26
8 Evaluating Interference Using Patient Specimens.....	26
8.1 Experimental Design.....	26
8.2 Comparative Measurement Procedure.....	27
8.3 Patient Populations.....	27
8.4 Experimental Procedure.....	28
8.5 Data Analysis.....	28
8.6 Interpretation of Results.....	31
9 Establishing, Validating, and Verifying Interference Claims.....	31
9.1 Establishing Interference Claims.....	32
9.2 Verifying Analytical Specificity.....	34
9.3 Validating Analytical Specificity.....	35
9.4 Verifying Interference and Specificity Claims.....	36

Contents (Continued)

10	Investigating Discrepant Patient Results.....	36
10.1	Verify System Performance.....	37
10.2	Evaluate Sample Quality	37
10.3	Confirm the Original Result.....	37
10.4	Identify Potentially Interfering Substances.....	38
10.5	Determine the Probable Interferent.....	38
10.6	Characterize the Interference	39
	References.....	40
	Appendix A. Guidelines for Specific Measurement Procedures	43
	Appendix B. Analyte Test Concentrations	46
	Appendix C. Interferent Test Concentrations	49
	Appendix D. Interference Test Concentrations for Endogenous Analytes	75
	Appendix E. Worksheets	79
	Appendix F. Calculation of Replicates for Dose-Response Tests	87
	Appendix G. Preparation of Test Solutions for Interference Testing	90
	Summary of Consensus Comments and Committee Responses	96
	Summary of Consensus/Delegate Comments and Committee Responses.....	101
	The Quality System Approach.....	104
	Related CLSI/NCCLS Publications.....	105

Foreword

Interfering substances can be a significant source of error in clinical laboratory measurements.¹⁻³ Such errors may, in some cases, represent a hazard to the patient. While precision is routinely monitored by internal quality control, and accuracy can be verified by comparison to reference materials or procedures, laboratories cannot easily detect error caused by interfering substances. Therefore, manufacturers of *in vitro* diagnostic (IVD) analytical systems must include evaluation of the effects of the potentially interfering substances in their risk analyses at the design stage.

Although continuously improving the specificity of measurement procedures is a desirable goal, compromise is sometimes necessary to meet the needs of clinical laboratories. The purpose of this document is to enable manufacturers and laboratories to evaluate interfering substances in the context of medical needs and to inform their customers of known sources of medically significant error. This guideline identifies potential hazards to be evaluated in the risk management process described in ISO 14971.⁴

To accommodate the variety of existing and future measurement procedures, we provided guidance instead of rigid protocols. The subcommittee struck a balance between consistency of structured protocols and flexibility to accommodate the technology being evaluated. Laboratorians and manufacturers need to understand the scientific concepts, make informed choices, and work together toward the common goal of improving patient care. Clearly, identifying an interference effect, evaluating its medical significance, determining its underlying cause, and ultimately improving the measurement procedure requires close cooperation between laboratory and manufacturer.

Background information is included to explain key chemical and statistical concepts. Please note that this document focuses on interference with analytical processes. It does not address physiological effects caused by drugs and their metabolites. The IFCC has issued a series of recommendations on drug effects⁵⁻⁷ that have been published as a compendium.⁸ Comprehensive literature surveys of the analytical and physiological effects of drugs and other substances have been published.⁹⁻¹¹

The basic substance of EP7-A2 remains unchanged. A thorough review of the exogenous and endogenous compounds recommended for testing was performed. Each drug or drug metabolite was systematically categorized into specific drug classes. This guideline was developed to inform the reader and provide a logical approach to complete the evaluation of the effects of potentially interfering compounds on the measurement procedure test results. The guideline is intended to make the decision easier by basing it on reasonable, objective criteria. We now ask the reader to give us comments and suggestions. Each comment and suggestion will be considered carefully at the next revision.

A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. Despite these obstacles, CLSI recognizes that harmonization of terms facilitates the global application of standards and is an area that needs immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the usage of terminology in this document with that of ISO, the following terms are used in EP7-A2:

The term *trueness* has replaced the term *accuracy* when referring to the closeness of agreement between the *average value* obtained from a large series of test results and an accepted reference value. *Accuracy*, in its metrological sense, refers to the closeness of the agreement between the result of a *single measurement* and a true value of a measurand, thus comprising both random and systematic effects.

The term *measurement procedure* has replaced the terms *method*, *analytical method*, and *analytical system* for a set of operations used in the performance of particular measurements according to a given method. The term *assay* has been replaced by *method*, *measurement procedure*, *measurement*, *analyze*, and *analysis* as appropriate. At this time, due to user unfamiliarity, the term *examination* is not used in this edition of EP7.

The terms *specimen* and *sample* are both used in this document, with *specimen* reserved for material collected directly from the patient, and *sample* reserved for aliquots of the patient specimen and for processed materials (e.g., PT samples, reference materials).

The term *analyte* is used appropriately in this document. The term *analyte* is used to represent the particular component of interest to the patient diagnosis, while the term *measurand* is used to describe the specific quantity that is measured by a particular measurement procedure (i.e., the measurand describes what is actually causing the result of the measurement). This important difference can be subtle, since it can be due to the detection of different measurands in the procedures being compared. The term *precision* is a measure of “closeness of agreement between independent test/measurement results obtained under stipulated conditions.”¹² The terms in this document are consistent with uses defined in the ISO 3534 and ISO 5725 series of standards.

At this time, due to user unfamiliarity and for the sake of the practicability of the guideline, it is important to point out that the working group has chosen not to replace the term *interfering substance* or *interferent* with the VIM (*International Vocabulary of Basic and General Terms in Metrology*) term *influence quantity* (i.e., quantity that is not the measurand but that affects the result of the measurement). The users of EP7 should understand that the fundamental meanings of the terms are identical, and to facilitate understanding, the terms are defined along with their ISO counterparts in the guideline’s Definitions section.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

Key Words

Evaluation, hazard analysis, interference, interferent, matrix effects, performance claims, risk management, specificity, validation, verification

Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition

1 Scope

This document is intended to serve two purposes:

- 1) to assist manufacturers and other developers of laboratory measurement procedures in characterizing the susceptibility of measurement procedures to interfering substances, by offering scientifically valid experimental designs, by specifying the relevant substances and concentrations to be tested, and by clarifying appropriate data analysis and interpretation, so that potential hazards can be evaluated and meaningful interference claims may be provided to users; and
- 2) to assist clinical laboratories in investigating discrepant results due to interfering substances, by defining a systematic investigation strategy, by specifying data collection and analysis requirements, and by promoting greater cooperation between laboratory users and manufacturers, so that new interferences can be identified, disclosed, and ultimately eliminated.

This guideline is intended for manufacturers of *in vitro* diagnostic medical devices and clinical laboratories.

Manufacturers and other developers of laboratory measurement procedures are responsible for characterizing the analytical performance of their procedures and analyzing hazards to patients caused by errors due to interfering substances. Manufacturers are required to provide information about interference susceptibility to those who use their systems. **NOTE:** The term “manufacturer,” for the purpose of this document, is used to mean anyone that develops a measurement procedure for use in a clinical laboratory.

Clinical laboratories are responsible for ensuring that measurement procedures are specific enough to meet the needs of their physician clients. Laboratories should also investigate discrepant results, identify interfering substances, and provide objective feedback to the manufacturers who supply their analysis systems.

2 Introduction

2.1 Measurement Procedures

Any measurement procedure, quantitative or qualitative, may be subject to interference. This document is written for a broad spectrum of measurement procedures and analyzers. Modification may be necessary to accommodate the particular characteristics of the procedure being evaluated. Two specific method principles (i.e., separation techniques and immunochemical measurement procedures) are discussed in Appendix A.

2.1.1 Specimen Type

Interferences with measurement procedures that use serum, plasma, whole blood, cerebrospinal fluid, urine, and most other body fluids may be evaluated using this guideline.

2.1.2 Interfering Substances

Potentially interfering substances may originate from the following endogenous and exogenous sources: